Astellas to co-promote AstraZeneca's Symbicort in Japan

4 August 2009

UK drug major AstraZeneca and Japan's Astellas Pharma have entered an agreement for the co-promotion of the former's Symbicort Turbuhaler (budesonide/formoterol, a dry powder inhaler), for the treatment of bronchial asthma in Japan.

Under the accord, the two companies will co-promote Symbicort Turbuhaler and Astellas will be responsible for distribution of the product. Astellas will make an upfront payment of 3.0 billion yen (about $31.5 million at current exchange rates) to AstraZeneca in addition to milestone payments of up to 5.5 billion yen depending on the achievement of certain sales and approval of an additional indication by the Japanese authority.

Symbicort Turbuhaler is not currently available in Japan. AstraZeneca submitted a New Drug Application in Japan in May 2007, the outcome of which is expected in the fourth quarter of 2009. Development is also under way for an indication to treat chronic obstructive pulmonary disease (COPD).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK